Peer-reviewed veterinary case report
Dog mast cell tumor treatment with tigilanol tiglate shows 12-month
By Jones, Pamela D et al.·Published in Journal of veterinary internal medicine·2021·QBiotics Group Limited, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.
- Species:
- dog
Plain-English summary
An 8-year-old dog with a mast cell tumor (a type of skin tumor) was treated with a single injection of tigilanol tiglate. After 28 days, the tumor was completely gone, and follow-up assessments showed that 89% of the dogs remained tumor-free at the treatment site even after 12 months. Most of the recurrences happened within the first six months after treatment. This suggests that tigilanol tiglate is an effective option for treating mast cell tumors in dogs, providing long-lasting results.
People also search for: dog mast cell tumor treatment · tigilanol tiglate for dogs · mast cell tumor recurrence in dogs
Abstract
BACKGROUND: Tigilanol tiglate (TT) is a novel small molecule approved by the European Medicines Agency for intratumoral treatment of mast cell tumors (MCTs) in dogs. In a randomized controlled clinical efficacy and safety study in the United States, 85 of 116 dogs that received a single TT injection achieved complete response (CR) of the treated MCT by day 28. OBJECTIVE: To evaluate the durability of the TT treatment response achieved at day 28 in the U.S. study by assessing MCT recurrence at the treatment site 6 and 12 months after TT administration. ANIMALS: Eighty-five dogs previously treated with TT. METHODS: Dogs that achieved CR at day 28 were assessed retrospectively for the presence or absence of MCT at the treatment site using records from clinical visits and telephone interviews with owners. Dogs unavailable at an assessment time were considered lost-to-follow-up and data for their last assessment used in the final analysis. RESULTS: By 12 months after TT treatment, 64 dogs remained evaluable, with 21 unavailable. Of evaluable patients, 57 (89%) remained tumor free at the treatment site and 7 (11%) had developed recurrence. All recurrences occurred within the first 6 months, predominantly (5/7, 71%) within the first 12 weeks. CONCLUSIONS AND CLINICAL IMPORTANCE: Tigilanol tiglate provided a durable long-term local response for the treatment of MCT in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33350511/